Lexicon Pharmaceuticals (Nasdaq: LXRX) will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) to review results and provide a business update.
According to Lexicon, investors can access the live webcast via the Events page of its investor website, with separate registration required to receive dial-in details for asking questions. An archived webcast will be available. Lexicon is a biopharmaceutical company with drug candidates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders, and other cardiometabolic indications.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Prior earnings-date events produced a 3.87% gain and 0% move over 24 hours. This scheduling notice s...
Analysis
Prior earnings-date events produced a 3.87% gain and 0% move over 24 hours. This scheduling notice sets the timing for results; moderate short positioning adds volatility risk, while the upcoming figures remain the key watchpoint.
"clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity"
Hypertrophic cardiomyopathy is a genetic heart condition in which the heart muscle becomes abnormally thick, making it harder for the heart to pump and for electrical signals to travel normally; think of a pump whose walls have thickened so it moves less efficiently. Investors care because the condition drives demand for diagnostics, drugs and devices, affects workforce and insurance costs, and can influence clinical trial results, regulatory approvals and liability exposure in healthcare-related companies.
preclinicalmedical
"a pipeline of drug candidates in discovery, preclinical, and clinical development"
Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.
cardiometabolicmedical
"and other cardiometabolic indications"
Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.
About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.
For Investor Inquiries: Lisa DeFrancesco Lexicon Pharmaceuticals, Inc. lexinvest@lexpharma.com
FAQ
When will Lexicon Pharmaceuticals (Nasdaq: LXRX) report its Q2 2026 financial results?
Lexicon Pharmaceuticals will report its Q2 2026 financial results on Thursday, August 6, 2026, before market open. According to Lexicon, the release will be followed by a management conference call and webcast the same morning to discuss results and provide a business update.
What time is the Lexicon Pharmaceuticals (LXRX) Q2 2026 earnings conference call on August 6, 2026?
The Lexicon Pharmaceuticals Q2 2026 earnings call is scheduled for 8:30 a.m. ET (7:30 a.m. CT) on August 6, 2026. According to Lexicon, management will discuss quarterly financial results and offer a broader business update during the live conference call and webcast.
How can investors access the Lexicon Pharmaceuticals (LXRX) Q2 2026 earnings webcast?
Investors can access the Lexicon Pharmaceuticals Q2 2026 earnings webcast via the Events page on the company’s investor website. According to Lexicon, participants wishing to ask questions must register separately to receive dial-in numbers and a unique PIN for the conference call.
Will a replay of the Lexicon Pharmaceuticals (LXRX) Q2 2026 earnings call be available?
Yes, a replay of the Lexicon Pharmaceuticals Q2 2026 earnings webcast will be available on the company’s website. According to Lexicon, an archived version of the webcast will remain accessible for investors who cannot listen to the live event on August 6, 2026.
How can I ask questions during the Lexicon Pharmaceuticals (LXRX) Q2 2026 earnings call?
To ask questions, participants must register online to receive dial-in numbers and a unique PIN. According to Lexicon, only registered participants with this PIN can join the conference line for the Q&A session during the Q2 2026 earnings call.
What therapeutic areas is Lexicon Pharmaceuticals (LXRX) focused on as of July 2026?
Lexicon focuses on drug candidates for neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders, and other cardiometabolic indications. According to Lexicon, its pipeline spans discovery, preclinical, and clinical development, aligning with its mission to pioneer medicines that transform patients’ lives across these disease areas.
